Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis

ObjectivePatients on dialysis are at high risk for severe COVID-19 and associated morbidity and mortality. We examined the humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in a maintenance dialysis population.DesignSingle-center cohort study.Setting and participantsAdult maintenance dialysis pat...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial stewardship & healthcare epidemiology : ASHE 2022-03, Vol.2 (1), p.e48-e48, Article e48
Main Authors: Li, Tingting, Gandra, Sumanth, Reske, Kimberly A., Olsen, Margaret A., Bommarito, Silvana, Miller, Candace, Hock, Karl G., Ballman, Claire A., Su, Christina, Le Dang, Na, Kwon, Jennie H., Warren, David K., Fraser, Victoria J., Farnsworth, Christopher W.
Format: Article
Language:English
Subjects:
Original
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivePatients on dialysis are at high risk for severe COVID-19 and associated morbidity and mortality. We examined the humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in a maintenance dialysis population.DesignSingle-center cohort study.Setting and participantsAdult maintenance dialysis patients at 3 outpatient dialysis units of a large academic center.MethodsParticipants were vaccinated with 2 doses of BNT162b2, 3 weeks apart. We assessed anti-SARS-CoV-2 spike antibodies (anti-S) ∼4-7 weeks after the second dose and evaluated risk factors associated with insufficient response. Definitions of antibody response are as follows: nonresponse (anti-S level,
ISSN:2732-494X
2732-494X
DOI:10.1017/ash.2022.31